Related Experiment Videos
Current and investigational therapies for AIDS-associated Mycobacterium avium complex disease
R C Rathbun1, E S Martin, V E Eaton
1College of Pharmacy, University of Texas, Austin 78712.
Abstract:
The epidemiology, pathogenesis, clinical manifestations, and treatment of Mycobacterium avium complex (MAC) infection are reviewed. MAC infection is one of the most common infections in AIDS patients. Its pathogenesis is poorly understood, but it is believed to develop by gastrointestinal colonization followed by systemic invasion. The relatively poor response to treatment may be partly accounted for by the tremendous mycobacterial load present by the time patients develop systemic symptoms. Clinically, MAC infection is difficult to differentiate from the signs and symptoms of AIDS or from other opportunistic infections. Signs and symptoms include fever, malaise, anorexia, night sweats, and weight loss; diarrhea and abdominal pain may also be present. There is no established therapy for MAC infection, although combinations of three to five antimicrobial agents are typically used. There has been consistently poor correlation between in vitro results and in vivo outcomes in the treatment of MAC infection. Currently, the role of treatment is mainly to suppress the progression of infection and to relieve symptoms. Recent in vitro studies and animal studies have revealed possible alternative agents and combinations of agents (e.g., macrolide antibiotics, quinolones, amikacin, cytokines) that may influence therapy of MAC infection. No known therapy for MAC has been shown to prolong survival in AIDS patients, possibly because of the high organism load that exists once patients become symptomatic. Research is needed to find improved methods for earlier detection of MAC infection, determine optimal dosage regimens of current antimycobacterial agents, develop better antimycobacterial drug-delivery systems (e.g., liposomes), and discover new antimicrobials with better activity against MAC and methods of immune modulation that will overcome immune system defects.
Insights
Mycobacterium avium complex (MAC) infections are common in AIDS patients, with poorly understood pathogenesis and limited treatment options. Current therapies aim to suppress infection and relieve symptoms, but new agents and detection methods are needed.
Area of Science:
- Infectious Diseases
- Immunology
- Microbiology
Background:
- Mycobacterium avium complex (MAC) infection is a significant opportunistic infection in individuals with Acquired Immunodeficiency Syndrome (AIDS).
- The pathogenesis of MAC infection, likely involving gastrointestinal colonization and systemic spread, remains incompletely understood.
- Clinical presentation of MAC infection often overlaps with AIDS symptoms and other opportunistic infections, complicating diagnosis.
Purpose of the Study:
- To review the epidemiology, pathogenesis, clinical manifestations, and treatment of Mycobacterium avium complex (MAC) infection.
- To highlight the challenges in treating MAC infection, particularly in the context of AIDS.
- To discuss potential future therapeutic strategies and research directions for MAC infection.
Main Methods:
- Review of existing literature on Mycobacterium avium complex (MAC) infection.
- Analysis of epidemiological data, pathogenesis theories, clinical signs, and current treatment approaches.
- Evaluation of recent in vitro and animal studies for novel therapeutic agents and strategies.
Main Results:
- MAC infection is a frequent complication in AIDS patients, characterized by non-specific symptoms like fever, malaise, and weight loss.
- Treatment response is often poor, potentially due to high mycobacterial loads at diagnosis and limited correlation between in vitro and in vivo efficacy.
- Current treatments focus on symptom management and disease suppression, with no established therapy shown to prolong survival in AIDS patients.
Conclusions:
- Effective treatment for MAC infection in AIDS patients remains a challenge, necessitating further research into early detection, optimal drug regimens, and novel therapeutic agents.
- Emerging therapies including macrolide antibiotics, quinolones, amikacin, and cytokines show promise but require further investigation.
- Future research should focus on improved diagnostics, drug delivery systems, new antimicrobials, and immune modulation strategies to combat MAC infection effectively.